Esperion Therapeutics (ESPR) Accumulated Expenses (2012 - 2026)

Esperion Therapeutics has reported Accumulated Expenses for 15 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 83.9% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 83.9% YoY), and the FY2025 full-year result was $4.1 million, down 79.0% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.7 million, down from $4.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $35.4 million in Q3 2022, with the low at $2.7 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $11.8 million across 5 years, with a median of $7.5 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 844.87% — and 2023, when it tumbled 90.24%.
• Esperion Therapeutics' Accumulated Expenses stood at $5.4 million in 2022, then surged by 360.71% to $25.0 million in 2023, then slipped by 21.62% to $19.6 million in 2024, then tumbled by 79.0% to $4.1 million in 2025, then slumped by 34.95% to $2.7 million in 2026.
• The last three Accumulated Expenses figures came in at $2.7 million (Q1 2026), $4.1 million (Q4 2025), and $18.6 million (Q3 2025), per Business Quant data.